Table 2. Clinical characteristics of patients with R-CDI and NR-CDI.
| R-CDI (n = 23) | NR-CDI (n = 31) | p value | |
|---|---|---|---|
| Hospitalization | |||
| Length of stay (mean days, range) | 29.55 (4–124) | 20.86 (4–59) | 0.181 |
| Intensive care unit, n (%) | 6 (26.09) | 10 (32.26) | 0.427 |
| Length of stay in ICU (mean days, range) | 14.77 (2–48) | 12.10 (2–48) | 0.460 |
| Prior antibiotics | |||
| Any antibiotic, n (%) | 30 (96.77) | 22 (95.65) | 0.675 |
| Length of exposure (mean days, range) | 21.48 (1–100) | 13.52 (1–52) | 0.132 |
| No. of antibiotics (mean) | 3.65 | 2.71 | 0.037* |
| Cephalosporins | 12 (54.54) | 8 (27.59) | 0.048* |
| Clindamycin | 18 (81.82) | 21 (72.41) | 0.329 |
| Macrolides | 21 (95.45) | 27 (91.10) | 0.605 |
| Fluoroquinolones | 10 (45.45) | 27 (91.10) | 0.000* |
| Vancomycin | 9 (40.91) | 21 (72.41) | 0.024* |
| Metronidazole | 19 (86.36) | 25 (86.21) | 0.657 |
| Carbapenems | 14 (63.64) | 17 (58.62) | 0.472 |
| CDI treatment | |||
| Vancomycin | 19 (86.36) | 24 (80.00) | 0.490 |
| Metronidazole | 13 (59.09) | 19 (63.33) | 0.415 |
| Metronidazole/vancomycin | 10 (45.45) | 16 (56.33) | 0.390 |
Data are no. (%) of patients, unless otherwise noted.
*Significant difference p value <0.05